NRIX Nurix Therapeutics, Inc.

$27.05

Nurix Therapeutics, Inc. (NRIX) is expected to report earnings on October 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.56 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +8.8% since its last earnings release on July 9, 2026.

Nurix Therapeutics, Inc. Missed Consensus Estimates
Thursday, July 9, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Aug 2026
Oct 12
Monday · 4:00 PM ET
Earnings Whisper
-
vs ($0.56)
Rev est $15.87M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $24.11

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Nurix Therapeutics, Inc.

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases.

Sector

Healthcare

Industry

Biotechnology